Repligen (NASDAQ:RGEN) Research Coverage Started at Canaccord Genuity Group

Canaccord Genuity Group assumed coverage on shares of Repligen (NASDAQ:RGEN) in a research report released on Tuesday morning, MarketBeat.com reports. The firm issued a hold rating and a $165.00 price objective on the biotechnology company’s stock.

Other equities research analysts have also recently issued reports about the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $205.00 price target on shares of Repligen in a research note on Thursday, September 26th. Wolfe Research initiated coverage on shares of Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. Canaccord Genuity Group initiated coverage on shares of Repligen in a report on Tuesday. They issued a “hold” rating and a $165.00 price objective on the stock. Wells Fargo & Company assumed coverage on shares of Repligen in a research note on Tuesday, August 27th. They set an “overweight” rating and a $180.00 target price for the company. Finally, StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research report on Friday, November 22nd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $185.20.

Repligen Stock Down 0.5 %

Shares of NASDAQ RGEN opened at $146.54 on Tuesday. The firm has a fifty day simple moving average of $144.07 and a two-hundred day simple moving average of $141.81. Repligen has a 12 month low of $113.50 and a 12 month high of $211.13. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $8.21 billion, a PE ratio of -396.04, a price-to-earnings-growth ratio of 4.64 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The business had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same period last year, the business posted $0.23 earnings per share. Repligen’s quarterly revenue was up 9.7% compared to the same quarter last year. Equities analysts expect that Repligen will post 1.54 earnings per share for the current year.

Institutional Investors Weigh In On Repligen

Several institutional investors have recently modified their holdings of RGEN. Toronto Dominion Bank lifted its stake in Repligen by 1.5% during the 2nd quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company’s stock valued at $656,000 after acquiring an additional 75 shares during the period. DekaBank Deutsche Girozentrale lifted its position in Repligen by 1.1% during the second quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company’s stock valued at $982,000 after purchasing an additional 89 shares during the period. MML Investors Services LLC lifted its position in Repligen by 2.7% during the third quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock valued at $503,000 after purchasing an additional 89 shares during the period. Ballentine Partners LLC boosted its holdings in Repligen by 6.2% in the third quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company’s stock worth $269,000 after purchasing an additional 105 shares during the last quarter. Finally, CWM LLC grew its position in Repligen by 36.3% in the 3rd quarter. CWM LLC now owns 428 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 114 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.